BTG Pactual Asset Management US’s iShares Biotechnology ETF IBB Stock Holding History

BTG Pactual Asset Management US’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.81M	Sell	14,799 -1,198	-7%	-$206K	0.17%	115
2026 Q1	$2.7M	Buy	15,997 +21	+0.1%	+$3.59K	0.23%	96
2025 Q4	$2.02M	Sell	15,976 -578	-3%	-$93.9K	0.2%	86
2025 Q3	$2.09M	Buy	16,554 +928	+6%	+$127K	0.1%	77
2025 Q2	$1.98M	Buy	15,626 +433	+3%	+$53.2K	0.22%	89
2025 Q1	$1.94M	Buy	15,193 +1,749	+13%	+$237K	0.21%	108
2024 Q4	$1.52M	Sell	13,444 -344	-2%	-$48.4K	0.16%	124
2024 Q3	$1.56M	Buy	13,788 +1,517	+12%	+$219K	0.13%	132
2024 Q2	$1.68M	Buy	+12,271	New	+$1.64M	0.25%	77

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

BTG Pactual Asset Management US's IBB Position: Q2 2026 in Review

BTG Pactual Asset Management US reduced its iShares Biotechnology ETF (IBB) stake by 7.5% in Q2 2026, selling an estimated $206K and leaving 14,799 shares worth $2.81M. The position accounts for 0.17% of the portfolio, ranked #115.

BTG Pactual Asset Management US first reported a position in IBB in Q2 2024 and has held it in 9 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

BTG Pactual Asset Management US held 14,799 shares of iShares Biotechnology ETF worth $2.81M as of Q2 2026.
BTG Pactual Asset Management US sold 1,198 iShares Biotechnology ETF shares in Q2 2026, an estimated $206K.
iShares Biotechnology ETF made up 0.17% of BTG Pactual Asset Management US's portfolio in Q2 2026, its #115 holding.
BTG Pactual Asset Management US first reported a position in iShares Biotechnology ETF in Q2 2024 and has held it in 9 quarters since.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q2 2026, filed 14 Aug 2026.